Pro-angiogenic genes in ovarian tumor endothelial cell isolates

US8440393B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US
• The University of MD Anderson Cancer Center · US

Inventors

• Michael J. Birrer · Potomac, US
• Tomas A. Bonome · Washington, US
• Anil K. Sood · Kullu, IN
• Chunhua Lu · Beijing, CN

Key dates

• Filing date: Aug 14, 2009
• Grant date: May 14, 2013
• Expiry date: Feb 24, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/136
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.